Advertisement
Jonas Ohlsson, former CEO at Mentice AB, has extensive experience of thebiotech industry and has held executive positions at PE Applied Biosystems,Kovalent AB and AstraZeneca. Significantly, Mr. Ohlsson previously guidedMentice through a similar growth period to the one that Cellectricon nowenters.
Advertisement
Dr. Mattias Karlsson, former acting CEO of Cellectricon, has beenappointed Chief Technical Officer (CTO). Dr. Karlsson will, in this new role,focus on managing the introduction of Cellectricon's new and enablingscreening systems.
Cellectricon's Chairman Axel Broms said: "The board is convinced thatthese appointments will secure the continued successful development ofCellectricon and strengthen the capacity as the Company is rapidly increasingits global businesses. It is with great joy we welcome Jonas Ohlsson toCellectricon."
Jonas Ohlsson added: "Cellectricon is a remarkable company with strongcustomer validation and well-earned reputation for providing groundbreakingproducts to the pharmaceutical and biotechnology industries. I'm thrilledwith the opportunity to drive its continued rapid development and expansionas the company is rolling out two screening systems developed in closecollaboration with the pharmaceutical industry."
About Cellectricon
Cellectricon AB, a Swedish biotech company, successfully providesgroundbreaking products to the pharmaceutical and biotechnology industries.Cellectricon's products address critical bottlenecks in the drug discoveryprocess and have been adopted by top-reference customers, including nine ofthe top ten pharmaceutical companies. In 2007 the company increased itsrevenue by almost 50%. In April 2008 Cellectricon launched the first of theirlarge-scale screening systems, Cellaxess(R)HT, developed in closecollaboration with one of the world's largest pharmaceutical companies.Cellaxess(R)HT is the only system on the market that, enables the large-scaledelivery of genetic material to a broad range of difficult to transfect celltypes, and that is tailor made for high throughput RNAi screening.Cellectricon's forthcoming products address a market that is estimated to be$1.4 US billion by 2010.
SOURCE Cellectricon AB
